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Background: Exclusive liver metastases occur in up to 40% of patients with uveal melanoma associated with
a median survival of 2–7 months. Single agent response rates with commonly available chemotherapy are below 10%.
We have investigated the use of fotemustine via direct intra-arterial hepatic (i.a.h.) administration in patients with uveal
melanoma metastases.
Patients and methods: A total of 101 patients from seven centers were treated with i.a.h. fotemustine,
administered intra-arterially weekly for a 4-week induction period, and then as a maintenance treatment every 3 weeks
until disease progression, unacceptable toxicity or patient refusal.
Results: A median of eight fotemustine infusions per patient were delivered (range 1–26). Catheter related
complications occurred in 23% of patients; however, this required treatment discontinuation in only 10% of the
patients. The overall response rate was 36% with a median overall survival of 15 months and a 2-year survival rate of
29%. LDH, time between diagnosis and treatment start and gender were significant predictors of survival.
Conclusions: Locoregional treatment with fotemustine is well tolerated and seems to improve outcome of this poor
prognosis patient population. Median survival rates are among the longest reported and one-third of the patients are
still alive at 2 years.
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introduction
Uveal melanoma is a rare disease, accounting for approximately
0.1% of all cancer deaths [1]. Its incidence is estimated at 0.6 per
100 000 persons/year and seems to remain stable over time,
while for cutaneous melanoma a five- to six-fold increase in
incidence has been observed [2, 3]. Uveal melanoma differs
from its cutaneous counterpart in terms of metastatic pattern
and prognosis. Muco-cutaneous melanoma basically spreads via
lymphatic vessels often giving rise to multiple locoregional
recurrences before systemic disease occurs. In contrast, uveal
melanoma metastasizes hematogenously and the liver is the
primary and, in up to 90% of patients, sole metastatic site [4, 5].
This specific oculo-hepatic tropism remains yet unexplained.
Depending on tumor size, the risk of recurrence and metastatic
spread is considerable, and the 5-year overall mortality rates
range from 20% for small primary tumors to more than 50%
for larger tumors [6]. In metastatic patients, reported median
survival times vary between 2 and 7 months and only 15% of
patients are alive after more than 1 year [7–9].
Metastases from uveal melanoma are considered resistant to
commonly available systemic chemo- or chemoimmunotherapy
with single agent response rates below 10%. Most therapies
are derived from the experience in cutaneous melanoma.
Agents such as dacarbazine (DTIC), cisplatin, interferon and
interleukin-2 (IL-2) have been evaluated. In the 1990s
fotemustine, a novel nitrosourea with activity against malignant
melanoma has been introduced in the clinic [10]. This alkylating
agent has a short half-life and a high first-pass liver extraction
leading to hepatic concentrations of eight to 47 times higher
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than in normal tissue [11, 12]. We have investigated the use of
fotemustine as a locoregional treatment via direct intra-arterial
hepatic administration in patients with metastases from uveal
melanoma. In a previous report, we demonstrated the feasibility
and good tolerance of this approach, as well as an encouraging
response rate of 40% and a 2-year survival rate of 23% [13].
We report here on an extended and multicenter experience
of 101 patients who were treated with intra-arterial hepatic
(i.a.h.) fotemustine.
patients and methods
patient selection
We report on a series of 101 consecutive patients treated between 1990 and
2004 with i.a.h. fotemustine. Data was extracted retrospectively from both
prospective clinical databases and from the medical charts of the following
institutions: University of Lausanne Hospitals, Switzerland (n = 66;
including 31 patients previously reported [13]), Institut Curie Paris, France
(n = 19), Ospedale Generale San Guiseppe of Empoli, Italy (n = 5), Benjamin
Franklin Hospital of the Free University of Berlin, Germany (n = 3), St Luc
University Hospital of Brussels, Belgium (n = 2) and the University
Hospitals of Tel Aviv and Jerusalem, Israel (n = 6).
Patients were initially enrolled into a prospective phase II feasibility trial.
The protocol was approved by the ethical committee. Based on this favorable
experience, all subsequent patients were treated according to this protocol.
All patients gave informed consent.
Principal eligibility criteria included a performance status of £2,
histologically confirmed uveal melanoma, liver metastases, the absence of
significant tumor bulk outside the liver, normal blood counts and an
adequate renal function. Impaired liver function was not an exclusion
criteria provided this was due to tumor involvement. Patients had to be
ambulatory and fit to undergo surgery for catheter placement. Patients
had not received prior chemotherapy.
chemotherapy schedule and drug administration
Fotemustine (Muphoran) was supplied by Servier, Paris, France, as
a freeze-dried sterile powder in vials containing 200 mg of active substance
diluted with 4 ml ethanol solvent. Before infusion, the drug was further
diluted in 250 ml of 5% injectable glucose solution and protected from light.
Fotemustine 100 mg/m2 was administered intra-arterially via the previously
placed catheter as a 4-h infusion. It was delivered weekly for a 4-week
induction period, followed by a 5-week rest and then as a maintenance
treatment every 3 weeks until disease progression, unacceptable toxicity or
patient refusal. In 22 patients, temozolomide at 100 mg/m2 was given for
2 days before the administration of fotemustine during the maintenance
phase aiming at methyl guanine methyl transferase (MGMT) depletion
[14, 15]. Antiemetic treatment was administered prophylactically using
ondansentron and methylprednisolone.
An implantable catheter connected to a subcutaneous access chamber
(Port-A-Cath) was surgically placed into the hepatic artery through the
gastroduodenal artery. Debulking surgery was performed whenever feasible.
follow-up visits and assessment of catheter related
complications
Clinical visits were performed weekly during the induction period and every
3 weeks during maintenance treatment and included a complete physical
examination, a full blood count and blood chemistry including serum liver
function tests. If hematotoxicity grade 3 or 4 was observed, full blood counts
were monitored weekly or biweekly until resolution to a grade £2. LDH and
alkaline phosphatase (AP) levels were recorded at baseline. Catheter-related
complications were assessed during the whole treatment period.
Toxicity was graded according to the International Common Toxicity
Criteria (NCI, NIH, version 2.0, March 1998).
response evaluation
Pretreatment tumor assessment, as well as response evaluation, was done
using computed tomography (CT) of the chest and abdomen. Response
evaluation was performed according to World Health Organization (WHO)
criteria [16] at the end of the 5-week rest period after induction and
subsequently after every 3 cycles during the maintenance phase. Complete
response (CR) was defined as the disappearance of all liver metastases,
partial response (PR) as a reduction of ‡50% in the sum of the products of
perpendicular diameters of all measurable metastases, and stable disease
(SD) as a reduction of £50% or an increase of <25%. Progressive disease
(PD) was defined as an increase of ‡25% in the sum of the products of
perpendicular diameters of all measurable metastases [17]. Response rate
was calculated as the proportion of patients presenting a CR or PR. For the
12 patients with extrahepatic metastases, no increase of pre-existing lesions
nor the occurrence of new extrahepatic metastases was allowed in order to be
considered as an objective response or stable disease.
statistical considerations
The primary end point of this study was overall survival (OS), which was
defined as time from diagnosis of liver metastases to death. Observation time
has been censored at the date of last contact for patients still alive, all survival
data was updated in Spring 2005. Statistical analyses were carried out by
means of the software package SPSS [18]. Survival percentages over time
have been calculated by the Kaplan–Meier method [19] and their
corresponding standard errors (SE) with Greenwood’s formula [20]. For
univariate analyses of OS the P values from the log-rank test [21] are
reported for each comparison considered. Estimated hazard ratios (HR) of
death, with respect to the indicated reference group, their 95% confidence
intervals (CI) and P values were calculated with (univariate and
multivariate) proportional-hazard-regression model [22] with appropriate
binary variables to identify each group of interest. The variables considered
were (the first category is the reference one for the HR): age (£60 versus >60
years versus unknown); performance status (0 versus ‡1 versus unknown);
gender; center (Lausanne versus others); liver resection (yes versus no
versus unknown); LDH level [normal versus >1.5 · upper limit of normal
(ULN) versus unknown]; alkaline phosphatase (AP) level (normal versus
abnormal versus unknown); year of diagnosis of ocular melanoma (£1989
versus 1990–99 versus ‡2000); extrahepatic metastases (yes versus no);
time from diagnosis of primary tumor to diagnosis of liver metastases
(£1 versus 1–3 versus >3 years); and time from diagnosis of metastases to
treatment start (£3 versus 3–6 versus >6 months). Backward elimination
(P value to enter 0.05, P value to leave P = 0.10) was used to select the
final model. Values of HR greater than unity indicate increased rates of
death with respect to the chosen reference category. All probability values
are for two-sided tests.
results
patient and tumor characteristics
A total of 101 patients from seven centers were included in this
analysis. Patients treated at the University Hospital of Lausanne
accounted for 65% of the patients. Patient characteristics are
summarized in Table 1; in an intent-to-treat analysis we did not
exclude patients with only incomplete information available.
The male:female ratio was 1:1 and the median age at the time of
diagnosis of liver metastases was 55 years (range 24–74). The
majority of patients had a good performance status at the start
of treatment with a median Eastern Cooperative Oncology
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Group (ECOG) stage of 0 (range 0–2) [17]. The liver was the
only site of metastases in 89 patients and the liver metastases
were histologically confirmed in the great majority of patients.
Twelve patients also had extrahepatic disease including skin,
bone, lung or peritoneal metastases, but were included because
liver was the main site of disease and the location determining
survival. Thirty-eight patients underwent debulking (non-
radical) surgery of liver metastases (metastasectomy,
segmentectomy, right or left hepatectomy) at the time of
catheter placement. Elevated baseline LDH levels were observed
in 21 patients and AP levels were abnormal in 31. The time from
diagnosis of the primary tumor to the diagnosis of liver
metastases was highly variable (median 34 months, range 3–332
months) with almost half of the patients developing metastatic
disease after 3 years, and in one patient distant spread occurred
as late as 28 years. The median time from diagnosis of liver
metastases to first administration of fotemustine was 1.9 months
(range 0.1–45 months). Six patients had been referred to the
medical oncologist later than 6 months after diagnosis of
hepatic metastases.
treatment delivery and complications
Overall, 918 infusions of fotemustine with a median of eight per
patient were delivered (range 1–26). The majority of the patients
(77%) received all four administrations of fotemustine during
the induction period (median four cycles, range 0–4). The
median number of maintenance cycles administered was five
(range 0–22). Seventeen patients did not proceed to
maintenance phase because of toxicity (n = 3), disease
progression (n = 10), one patient refused to continue
chemotherapy and for three patients no information was
available. Eighty-four patients started maintenance therapy and
received a median of five additional cycles (range 1–22).
Eighteen patients received fotemustine for more than 6 months
(up to 25 months), with low toxicity throughout the treatment
duration.
Severe grade 3/4 toxicity was observed in 11% of patients,
mainly hematotoxicity (4%). In addition, grade 2 hematotoxicity,
and in particular thrombocytopenia, occurred in 11% of
patients.
Placement of an intra-arterial catheter is associated with a risk
of catheter thrombosis, dislocation and, to a lesser extent,
catheter stenosis/obstruction or leakage. Overall, complications
related to the catheter, namely thrombosis, occurred in 21
patients, usually only after several months of treatment. More
than three-quarters of the patients with a catheter thrombosis
could nevertheless complete the chemotherapy as planned. Early
treatment discontinuation due to the catheter was necessary in
nine patients after a median treatment duration of 4 months.
Two of them presented catheter thrombosis, two of them
catheter stenosis/obstruction and two of them dislocation.
Organ damage in the form of pancreatitis and sclerosing
cholangitis developed in two patients. One patient could not
start chemotherapy because of the appearance of a post-
operative icterus, following the surgical procedure in the context
of extensive liver disease and hepatic insufficiency.
therapeutic activity
Of the 101 patients, 21 achieved a partial response and 15
patients had a radiological complete response, for an overall
response rate of 36%. In 48 patients the disease was stable, for
a median duration of 9.4 months. Seventeen per cent of the
patients had progressive disease at first radiological assessment.
Median overall survival for the whole group was 15 months
(95% confidence interval (CI) 12.1–17.6 months) with
a 1-year survival rate of 67% (95% CI 57–75%). Twenty-nine
per cent of the patients were still alive at 2 years and 12% at
3 years (Figure 1).
Multivariate and univariate analysis did not show any impact
of age, performance status, the presence of extrahepatic
disease at baseline, or the interval between diagnosis of primary
Table 1. Patient characteristics
Characteristic No. of patients
Total 101
Gender
Male 50
Female 51
Age (years)
Median 55 (range 24–74)
24–60 59
>60 36
Unknown 6
PS at diagnosis
Median 0 (range 0–2)
0 64
1 + 2 28
Unknown 9
Extrahepatic metastases
Yes 12
No 89
Liver resection
Yes 39
No 51
Unknown 11
Elevated LDH at diagnosis
Yes 21
No 66
Unknown 14
Abnormal alk. phosphatase at diagnosis
Yes 31
No 41
Unknown 29
Time interval from diagnosis of ocular melanoma to
hepatic metastases
Median 34 months (range 3–332)
<1 year 11
>1–3 years 42
>3–28 years 48
Time interval from diagnosis of liver metastases to
treatment start
Median 1.9 months (range 0.1–45)
<3 months 77
>3–6 months 18
>6 months 6
PS, performance status.
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tumor and liver metastases on outcome. After scrutiny of all
variables according to a forward selection approach, LDH,
time between diagnosis of liver metastases and treatment
start, resection of liver metastases as well as gender were
significant predictors of survival (Table 2). Elevated LDH
levels were the strongest predictors for survival with a median
survival time of 9.5 months compared with 19.4 months with
levels £1.5 · ULN (multivariate HR = 3.7, 95% CI 2.0–7.0,
P < 0.001) and 15.5 months for patients with unknown levels
(multivariate HR = 0.9, 95% CI 0.4–1.8, P < 0.710). Male gender
was an unfavorable prognostic factor for survival in this series
(multivariate HR = 1.8, 95% CI 1.1–3.0, P = 0.026). Resection
of liver metastases was performed in 39 patients. The median
survival of these patients was 25 months (95% CI 19.8–30.5)
compared with 13 months (95% CI 10.0–15.6) for those who
did not have resection and 13.4 months (95% CI 11.0–15.7) for
patients with unknown status (P = 0.001). In multivariate
analysis patients with resection showed a better though not
significant survival; significance was observed for patients with
unknown status. The interval between diagnosis of liver
metastases and the time of chemotherapy start was shown to be
related to patients’ survival. Patients who started chemotherapy
later than 6 months after diagnosis incurred a reduced risk of
death; however, this was of borderline significance.
discussion
We report here on an extended experience of intra-arterial
intrahepatic chemotherapy with fotemustine in patients with
metastatic uveal melanoma to the liver. To our knowledge this is
the largest series of homogeneously treated patients with this
rare disease expanding on our previously reported local
experience [13]. The study population is representative of the
type of patient presenting with metastatic uveal melanoma.
Almost 90% of patients presented with liver involvement as
a single metastatic site at diagnosis, in line with the particular
oculo-hepatic tropism of uveal melanoma cells. Hence, it is the
metastatic liver involvement that accounts for the poor outcome
of these patients with median survival rates that do not exceed
a year in historical series. Interestingly, patients presenting only
extrahepatic metastasis have a better prognosis [7–9].
There have been few treatment options for this patient
population in the past. Most systemic chemo-/immunotherapy
regimens, similar to cutaneous melanoma, demonstrated even
less activity in uveal melanoma [23]. Both tumor entities differ
considerably in their molecular profile and biological behavior
despite their common embryological origin [24–26]. Uveal
melanoma represents a distinct entity. Patients with metastatic
uveal melanoma should be considered for specific treatment
protocols, rather than being included in trials for metastatic skin
melanoma.
Since the liver represents the critical organ determining
patients’ outcome, locoregional treatment regimens have been
developed in the past. Fotemustine is a third-generation
nitrosourea with a high hepatic extraction. In early clinical trials
it has shown promising activity in uveal melanoma [13, 27–30].
Furthermore, this prolonged arterial intrahepatic
administration over 4 h reduced the plasma AUC by 50%,
translating into decreased systemic toxicity compared with the
intravenous schedule [11].
The previously reported experience in a single center phase II
trial on 30 patients [13] has been confirmed in the present
analysis on 101 patients treated in different institutions. We
observed a 36% response rate (including 15% complete
responses), which reflects the excellent locoregional activity of
fotemustine. This translates into a median overall survival of
15 months with almost one-third of the patients still alive at
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Figure 1. Overall survival of patients since diagnosis of liver metastasis.
Survival percentages are shown over time in months. Percentages have
been calculated according the Kaplan–Meier method. Median overall
survival for the whole group was 15 months (95% CI 12.1–17.6). Curves
are truncated at 5 years (numbers show censored observations).
Table 2. Factors influencing survival by multivariate Cox regression
with backward elimination
HR 95% CI for HR P value
LDH > 1.5 UNL
No 1 Reference
Yes 3.7 2.0–7.0 <0.001
Unknown 0.9 0.4–1.8 0.710
Liver resection
No 1 Reference
Yes 0.7 0.4–1.3 0.253
Unknown 2.4 1.1–4.9 0.021
Gender
Female 1 Reference
Male 1.8 1.1–3.0 0.026
Months from liver metastasis to
chemotherapy
<3 months 1 Reference
>3–6 months 1.5 0.8–2.8 0.229
>6 months 0.3 0.1–1.1 0.067
HR, hazard ratios of death; CI, confidence intervals.
Estimated hazard ratios (HR) of death are calculated with respect to
the indicated reference group.
Annals of Oncology original article
Volume 17 | No. 4 | April 2006 doi:10.1093/annonc/mdl009 | 581
2 years. These results compare favorably with other locoregional
treatment options such as arterial chemoembolization or
isolated hepatic perfusion [31–33]. The latter techniques are
associated with substantial morbidity and mortality,
necessitating prolonged hospitalization. Locoregional
chemotherapy with fotemustine can be delivered on an
outpatient basis, improves local control and has a favorable
systemic toxicity profile.
The need for catheter placement and associated complications
is a major obstacle to all locoregional treatments (i.e. arterial
chemoembolization, isolated hepatic perfusion) [27, 32–34].
Although in the present series, almost one-quarter of the
patients experienced a complication due to the arterial catheter,
these complications required treatment discontinuation in only
nine patients. Our experience is in agreement with reports of
intra-arterial chemotherapy for liver metastases of colorectal
cancer. In these reports, 14% of patients experienced catheter-
related complications rendering the infusional device unusable,
and were mostly thrombosis and catheter dislocation [35, 36].
Hematotoxicity reported in this series is lower compared with
reports of intravenous fotemustine administration. This is
possibly due to the first pass effect and hepatic extraction.
However, due in part to the retrospective data collection, there
may be an underestimation of the toxicity.
Retrospective series attempted to define prognostic factors for
patients with uveal melanoma. The strongest predictive factors
for metastatic spread are macroscopic and histopathologic
findings of the primary tumor [37–39]. Features like invasion of
the ciliary body, the sclera or the anterior equator of the eye,
tumor diameter as well as epitheloid cells, monosomy of
chromosome 3 [40] and patterns of vascular mimicry [41] have
been uniformly associated with increased risk for distant
metastases. However, the determination of prognostic factors
in the metastatic setting is less clear and controversial results
have been reported on factors like age, gender, debulking
surgery or biochemical parameters (serum alkaline phosphatase,
cGT and LDH) [42–44]. Our present data confirm elevated
LDH to be a significant negative prognostic factor. Although
the influence of resection of liver metastases has never been
studied within a randomized trial, previous reports suggest
that metastasectomy or surgical tumor reduction showed no
prognostic significance. Only macroscopically complete tumor
resection seemed to improve patients’ survival [5]. In our
study, in multivariate analysis, patients with tumor resection
showed a better, though not statistically significant, survival.
This may reflect complete tumor resection performed in some
of the operated patients, but also patient selection of the
fittest for surgery. How far disease evolution is different between
men and women remains controversial. In our series, male
gender has been shown to be a negative prognostic factor for
survival. A long interval between the time of diagnosis of liver
metastases and treatment start had a favorable prognostic
impact. Interpretation of this finding should be handled with
caution due to the small group of patients (six). It might
represent a selection of patients with a favorable natural history
of metastatic ocular melanoma. However, their exclusion
from statistical analysis does not modify overall survival.
In summary, we confirmed in an extended patient population
that intra-arterial, intrahepatic fotemustine is an effective and
well-tolerated treatment against liver metastases from uveal
melanoma. Median survival rates are among the longest
reported and one-third of the patients were still alive at 2 years.
Compared with historical series and systemic treatment
approaches, locoregional treatment with fotemustine seems to
improve outcome of this poor prognosis patient population [28,
45–47]. However, although a non-randomized comparative trial
between intra-arterial hepatic and intravenous administration
of fotemustine could demonstrate a higher response rate with
the locoregional approach, it did not translate into a significant
benefit in overall survival [28]. Improved outcomes with recent
systemic treatments may also reflect patient selection and earlier
detection of metastasis (lead time bias) with median survival
rates comparable to our series even in the absence of a
objective antitumor response [45, 48]. This underlines the
importance of prospective controlled trials before embracing
a new treatment approach. The melanoma group of the
European Organisation for Research and Treatment of Cancer
(EORTC) recently opened a large phase III trial (EORTC
18021), comparing intra-arterial hepatic fotemustine
administration with intravenous systemic fotemustine. The
primary end point of this trial is overall survival [49].
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